Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

NCT00004856 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Distal Urethral Cancer
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Proximal Urethral Cancer
Recurrent Bladder Cancer
Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Recurrent Urethral Cancer
Stage IV Bladder Cancer
Transitional Cell Carcinoma of the Bladder
Urethral Cancer Associated With Invasive Bladder Cancer

Interventions

BIOLOGICAL: trastuzumab

Sponsor

National Cancer Institute (NCI)